- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06322303
Effect of Cannabidiol (CBD) on Vision and Driving
March 20, 2024 updated by: Sonia Ortiz Peregrina, Universidad de Granada
Effect of Cannabidiol (CBD) Consumption on Visual Function and Driving Performance
The use of cannabis with ∆9-tetrahydrocannabinol (THC) content has been shown to have negative effects on vision and driving.
The use of other cannabinoids, such as cannabidiol (CBD), which is not attributed with a psychoactive effect, is increasing significantly.
This project aims to investigate whether consuming CBD can negatively affect visual function by assessing a wide range of visual parameters and whether these changes may pose a risk for everyday activities such as driving.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Granada, Spain, 18071
- University of Granada
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Being an occasional cannabis and/or cannabidiol user
- Have a current driving licence
- Have at least one year's driving experience
- Drive at least once a week
- Monocular visual acuity of at least 6/6 (Snellen) with habitual correction for driving
- Absence of binocular disorders
Exclusion criteria:
- Certain past or present medical conditions
- Current cannabis or alcohol use disorder
- Use of other drugs
- Pregnancy or lactation
- Simulator sickness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo (CBD 0%)
Participants are required to vaporize a placebo at 0% CBD concentration
|
Participants are required to vaporize placebo at 0% CBD concentration
|
Experimental: CBD 15%
Participants are required to vaporize CBD at a concentration of 15%.
|
Participants are required to vaporize CBD at a concentration of 15%.
|
Experimental: CBD 30%
Participants are required to vaporize CBD at a concentration of 30%.
|
Participants are required to vaporize CBD at a concentration of 30%.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Overall Driving Performance Score (ODPS) after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
|
To obtain the ODPS, Z-scores were calculated from individual parameters such as the standard deviation of the lateral lane position or the distance travelled into the opposite lane.
The z-score is defined as a measure of how many standard deviations an individual value is below or above the group mean.
The average Z-score of the individual driving variables is called the ODPS.
|
Participants are assessed 20 minutes after vaporization
|
Change in motion detection sensitivity after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
|
The subject has to indicate the direction of movement of a pattern of moving dots.
The percentage of correct answers is obtained for different degrees of coherence.
|
Participants are assessed 20 minutes after vaporization
|
Change in contrast sensitivity after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
|
Contrast thresholds are obtained for different spatial frequencies
|
Participants are assessed 20 minutes after vaporization
|
Change in visual acuity after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
|
Visual acuity is assessed with a commercial test for distance vision.
|
Participants are assessed 20 minutes after vaporization
|
Change in fixations after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
|
The number of fixations made on different stimuli of interest in a task environment is counted using an eye tracker system.
|
Participants are assessed 20 minutes after vaporization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Driving simulator: standard deviation of the lateral lane position (SDLP)
Time Frame: Participants are assessed 20 minutes after vaporization
|
Participants are assessed 20 minutes after vaporization
|
|
Distance travelled outside the lane
Time Frame: Participants are assessed 20 minutes after vaporization
|
The SDLP assesses the lane weaving that the subject performs in the lane and indicates whether the vehicle's position is consistent.
|
Participants are assessed 20 minutes after vaporization
|
Mean speed
Time Frame: Participants are assessed 20 minutes after vaporization
|
Average speed is obtained and analyzed in relation to the speed limits for different sections.
|
Participants are assessed 20 minutes after vaporization
|
Angular velocity of the steering wheel
Time Frame: Participants are assessed 20 minutes after vaporization
|
The angular velocity of the steering wheel is a metric that indicates the subject's ability to maintain the vehicle's position.
|
Participants are assessed 20 minutes after vaporization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2023
Primary Completion (Actual)
September 30, 2023
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
February 29, 2024
First Submitted That Met QC Criteria
March 13, 2024
First Posted (Actual)
March 21, 2024
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-EXP-194-UGR23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use
-
Centre hospitalier de l'Université de Montréal...RecruitingCannabis | Cannabis Dependence | Cannabis Use | Cannabis Smoking | Cannabis Use, UnspecifiedCanada
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Food and Drug Administration (FDA)Not yet recruitingTobacco Use | Cannabis | Cannabis Use | Vaping | THC | Cannabis SmokingUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Hartford HospitalYale UniversityNot yet recruitingMarijuana Use | Cannabis Use | Cannabis Intoxication
-
McMaster UniversityCenter for Medicinal Cannabis ResearchNot yet recruitingCannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe
Clinical Trials on Placebo (CBD 0%)
-
Centre hospitalier de l'Université de Montréal...Completed
-
Hartford HospitalYale UniversityActive, not recruiting
-
Johns Hopkins UniversityCultivate BiologicsCompleted
-
University of Texas at AustinWay West Wellness; SunFlora.IncSuspendedAnger | Sleep Disturbance | Anxiety Depression | Substance Abuse | Alcohol Abuse | Stress ReactionUnited States
-
Canopy Growth CorporationNM Clinical Research & Osteoporosis Center, Inc.Terminated
-
Timothy L. BrownNational Highway Traffic Safety Administration (NHTSA); Cognitive Research... and other collaboratorsCompletedDriving Under the Influence | Driving BehaviorUnited States
-
University of CalgaryNot yet recruitingChronic Migraine
-
University of California, San DiegoCenter for Medicinal Cannabis Research; California Department of Cannabis Control...Recruiting
-
Khon Kaen UniversityRecruitingMalnutrition | Systemic Sclerosis | Loss of AppetiteThailand
-
Johns Hopkins UniversitySubstance Abuse and Mental Health Services Administration (SAMHSA)CompletedCannabis | Drug EffectUnited States